Literature DB >> 20298981

2010 Alzheimer's disease facts and figures.

.   

Abstract

Alzheimer's disease (AD) is the seventh leading cause of all deaths in the United States and is virtually tied with the sixth leading cause of death-diabetes. AD is the fifth leading cause of death in Americans aged 65 and older. Although other major causes of death have been on the decrease, deaths because of AD have been rising dramatically. Between 2000 and 2006, heart disease deaths decreased 11.1%, stroke deaths decreased 18.2%, and prostate cancer-related deaths decreased 8.7%, whereas deaths because of AD increased 46.1%. Older African-Americans and Hispanics are more likely than older white Americans to have AD or other dementia. Current estimates are that African-Americans are about 2 times more likely, and Hispanics about 1.5 times more likely, than their white counterparts to have these conditions. However, the relationship of race and ethnicity to the development of AD and other dementias is complex and not fully understood. In 2009, nearly 11 million family and other unpaid caregivers provided an estimated 12.5 billion hours of care to persons with AD and other dementias; this care is valued at nearly $144 billion. Medicare payments for services to beneficiaries aged 65 years and older with AD and other dementias are three times higher than for beneficiaries without these conditions. Total payments for 2010 for health care and long-term care services for people aged 65 and older with AD and other dementias are expected to be $172 billion (not including the contributions of unpaid caregivers). An estimated 5.3 million Americans have AD; approximately 200,000 persons under age 65 with AD comprise the younger-onset AD population. Every 70 seconds, someone in America develops AD; by 2050 the time of every 70 seconds is expected to decrease to every 33 seconds. Over the coming decades, the baby boom population is projected to add 10 million people to these numbers. In 2050, the incidence of AD is expected to approach nearly a million people per year, with a total estimated prevalence of 11-16 million people. Dramatic increases in the numbers of "oldest old" (aged 85 years and older) across all racial and ethnic groups will also significantly affect the numbers of people living with AD. This report provides information to increase understanding of the public health effect of AD, including incidence and prevalence, mortality, costs of care, and effect on caregivers and society in general. This report also sets the stage for better understanding the relationship between race and ethnicity and the development of AD and other dementias. 2010 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20298981     DOI: 10.1016/j.jalz.2010.01.009

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  187 in total

1.  CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease.

Authors:  Michael R Sierks; Gaurav Chatterjee; Claire McGraw; Srinath Kasturirangan; Philip Schulz; Shalini Prasad
Journal:  Integr Biol (Camb)       Date:  2011-11-10       Impact factor: 2.192

Review 2.  Quantitative structural MRI for early detection of Alzheimer's disease.

Authors:  Linda K McEvoy; James B Brewer
Journal:  Expert Rev Neurother       Date:  2010-11       Impact factor: 4.618

Review 3.  Quantifying factors for the success of stratified medicine.

Authors:  Mark R Trusheim; Breon Burgess; Sean Xinghua Hu; Theresa Long; Steven D Averbuch; Aiden A Flynn; Alfons Lieftucht; Abhijit Mazumder; Judy Milloy; Peter M Shaw; David Swank; Jian Wang; Ernst R Berndt; Federico Goodsaid; Michael C Palmer
Journal:  Nat Rev Drug Discov       Date:  2011-10-31       Impact factor: 84.694

4.  A comprehensive genetic association study of Alzheimer disease in African Americans.

Authors:  Mark W Logue; Matthew Schu; Badri N Vardarajan; Jacki Buros; Robert C Green; Rodney C P Go; Patrick Griffith; Thomas O Obisesan; Rhonna Shatz; Amy Borenstein; L Adrienne Cupples; Kathryn L Lunetta; M Daniele Fallin; Clinton T Baldwin; Lindsay A Farrer
Journal:  Arch Neurol       Date:  2011-12

5.  Psychotropic medication burden and factors associated with antipsychotic use: an analysis of a population-based sample of community-dwelling older persons with dementia.

Authors:  YongJoo Rhee; John G Csernansky; Linda L Emanuel; Chang-Gok Chang; Joseph W Shega
Journal:  J Am Geriatr Soc       Date:  2011-09-23       Impact factor: 5.562

6.  Alzheimer's disease clinical trials: changing the paradigm.

Authors:  Jeffrey L Cummings
Journal:  Curr Psychiatry Rep       Date:  2011-12       Impact factor: 5.285

7.  Role of RanBP9 on amyloidogenic processing of APP and synaptic protein levels in the mouse brain.

Authors:  Madepalli K Lakshmana; Crystal D Hayes; Steven P Bennett; Elisabetta Bianchi; Konda M Reddy; Edward H Koo; David E Kang
Journal:  FASEB J       Date:  2012-01-31       Impact factor: 5.191

8.  Effect of leisure activities on inflammation and cognitive function in an aging sample.

Authors:  Feng Lin; Elliot Friedman; Jill Quinn; Ding-Geng Din Chen; Mark Mapstone
Journal:  Arch Gerontol Geriatr       Date:  2012-02-27       Impact factor: 3.250

Review 9.  Molecular brain imaging in the multimodality era.

Authors:  Julie C Price
Journal:  J Cereb Blood Flow Metab       Date:  2012-03-21       Impact factor: 6.200

Review 10.  Creativity and dementia: a review.

Authors:  Massimiliano Palmiero; Dina Di Giacomo; Domenico Passafiume
Journal:  Cogn Process       Date:  2012-03-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.